"Japan is now facing the same situation as Europe came across several years ago in losing its international competitiveness in the pharmaceutical sector," Jean-Francois Dehecq, vice president of the European Federation of Pharmaceutical Industries and Associations and chairman of France's drug giant Sanofi-Aventis, said at a press conference in Tokyo.
Mr Dehecq spoke of the reasons for the loss of its international competitiveness by the Japanese pharmaceutical industry, how to improve both the environment for clinical trials and the drug review and approval system in Japan.
Stakeholder communication in Europe "has improved"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze